The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK

European Journal of Gastroenterology and Hepatology

Volumn 28, Issue 2, 2016, Pages 173-180

  McEwan, Phil ^a,c,e   Bennett, Hayley ^a   Ward, Thomas ^a   Webster, Samantha ^a   Gordon, Jason ^a,d   Kalsekar, Anupama ^b   Yuan, Yong ^b   Brenner, Michael ^b  

^a HEOR   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c SWANSEA UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e NONE   (United Kingdom)

Author keywords

Chronic hepatitis C; Cost'utility analysis; Cost effectiveness; Daclatasvir; Direct acting antivirals; Hepatitis C virus

Indexed keywords

BOCEPREVIR; DACLATASVIR; PEGINTERFERON ALPHA; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CHRONIC HEPATITIS C; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GENOTYPE; HEPATITIS C; HIDDEN MARKOV MODEL; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT INDICATION; UNITED KINGDOM; COMPUTER SIMULATION; DRUG COST; DRUG EFFECTS; ECONOMIC MODEL; ECONOMICS; GENETICS; GREAT BRITAIN; HEPACIVIRUS; HEPATITIS C, CHRONIC; MARKOV CHAIN; PHENOTYPE; TIME FACTOR; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DRUG COSTS; GENOTYPE; GREAT BRITAIN; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; MARKOV CHAINS; MODELS, ECONOMIC; PHENOTYPE; PROTEASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84952630005     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000510     Document Type: Article

References (61)

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60:392-420.
2. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection; 2014. Available at: htt p://www.who.int/HIV/pub/hepatitis/hepatitis-c-guidelines/en/. [Accessed 1 September 2015].
3. Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, et al. Increasing prevalence of HCC and c irrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2010; 1404:e1.
4. Public Health England, Health Protection Scotland, Public Health Wales, et al. Hepatitis C in the UK: 2014 report; 2014; updated September 2014. Available at: https://www.gov.uk/government/publications/hepa titis-c-in-the-uk. [Accessed 1 September 2015].
5. American Association for the Study of Liver Disea ses, Infectious Diseases Society of America, International Antiviral Society-USA. Recommendations for testing, managing and treating hepatitis C. 2014; updated September 2014. Available at: http://www.hcvguidelines.org/. [Accessed 1 September 2015].
6. Afdhal NH. Hepatitis C viral infection in difficult-to-treat populations: an overview. Clinical Liver Disease 2012; 1:63-64.
7. Kemmer N, Neff GW. Mana ging chronic hepatitis C in the difficult-totreat patient. Liver Int 2007; 27:1297-1310.
8. European Medicines Agenc y. European Medicines Agency recommends approval of Daklinza in chronic hepatitis C; 2014; updated June 2014. Available at: http://www.ema.europa.eu/docs/en-GB/docu ment-library/Press-release/2014/06/WC500169370.pdf. [Acces sed 1 September 2015].
9. Public Health England. Commissioning template for estimating HCV prevalence by DAT and numbers eligible for treatment; 2014; updated July 2014. Available at: http://www.hpa.org.uk/Topic s/InfectiousDiseases/InfectionsAZ/HepatitisC/EpidemiologicalData/. [Accessed 1 September 2015].
10. Public Health England, Health Protection Scotland, Public Health Wales, et al. Hepatitis C in the UK: 2013 r eport; 2013; updated June 2014. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/364074/Hepatitis-C-in-the-UK-2013.pdf. [Accessed 13 October 2015].
11. Medical Research Fo undation, Nottingham University Hospitals NHS Trust. HCV Research UK: Host and viral factors associated with outcomes of infection with hepatitis C virus; 2014. Available at: http://public. ukcrn.org.uk/search/StudyDetail.aspx?StudyID= 11582. [Accessed 13 October 2015].
12. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabby J. Pegylated interferon alpha-2a and-2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004; 8:iii-iv. 1-125.
13. Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007; 11:1-205. iii.
14. McEwan P, Kim R, Yuan Y. Ass essing the cost utility of responseguided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl Health Econ Health Policy 2013; 11:53-63.
15. McEwan P,Ward T,Yuan Y,Kim R,L'italien G The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology 2013 58 54-64.
16. McEwan P, Ward T, Chen C-J, Lee M-H, Yang H-I, Kim R, et al. Estimating the incidence and prevalence of chronic hepatitis C infection in Taiwan using back projection. Value Health Region Issues 2014; 3:5-1 1.
17. Townsend R, McEwan P, Kim R, Yuan Y. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health 2011; 14:1068-1077.
18. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a metaanalysis and meta-regression. Hepatology 2008; 48:418-431.
19. Office of National Statistics. National Life Tables, 2010-2012: UK reference tables; 2013; updated 14 October 2014. Available at: http://www.ons.gov.uk/ons/publications/re-refe rence-tables.html?edition = tcm%3A77-325699. [Accessed 1 September 2015].
20. Office of National Statistics. Mortality statistics: deaths registered in England and Wales (Series DR), 2012; 2013. Availab le at: http://www. ons.gov.uk/ons/publications/re-reference-tables.html?edition = tcm%3A77-325289. [Accessed 1 September 2015].
21. Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima V D, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-Acting antivirals. Hepatology 2013; 58:1598-1609.
22. Janssen Ltd. Telaprevir for the treatment of genotype 1 chronic hepatitis C. 2011. Available at: https://www.nice.org.uk/guidance/TA252/documents/hepatitis-c-genotype-1-telaprevir-janssen2. [Accessed 13 October 2015].
23. Merck Sharp & Dohme Ltd. Hepatitis C (genotype 1)-boceprevir. 2011. Available at: https://www.nice.org.uk/guidance/TA253/docu ments/hepatitis-c-genotype-1-boceprevir-merck-sharp-And-dohme2 . [Accessed 13 October 2015].
24. Janssen Ltd. Simeprevir for the treatment of genotype 1 and genotype 4 chronic hepatitis C. 2014. Available at: https://www.nice.org.uk/gui dance/ta331/documents [Accessed 13 October 2015].
25. Younossi Z, Stepanova M, Cure S, Bourrhis F, Nader F, Hunt S. Estimating Health Status Using EQ-5D for Chronic Hepatitis C (CH-C) Patients Treated with Sofosbuvir Containing Regimens. London: EASL 2014; 2014.
26. Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical tri al. JAMA 2013; 310:804-811.
27. Hezode C, Alric L, Brown A, Hassanein T, Rizzetto M, Buti M, et al. Daclatasvir in combination with peginterferon alfa-2a and ribavirin for treatment-naive p atients with HCV genotype 4 infection: phase 3 COMMAND-4 results. Philadelphia: IDWeek; 2014.
28. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir pl us sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-221.
29. Haymarket Media Group Ltd. Monthly Index of Medical Specialities (MIMS); 2015. Available at: http://www.mims.co.uk. [Accessed 1 September 2015].
30. Personal Social Services Research Unit. Unit costs of health & social care 2013; 2013. Available at: http://www.pssru.ac.uk/pr oject-pages/unit-costs/2013/. [Accessed 13 October 2015].
31. McEwan P, Ward T, Bennett H, Kalsekar A, Webster S, Brenner M, Yuan Y. Estimating the clinical and economic benefit associated with in cremental improvements in sustained virologic response in chronic hepatitis C. PLoS One 2015; 10:e0117334.
32. Bristol-Myers Squibb Pharmaceuticals Ltd. Summary of product characteristics. Daklinza® 30 mg and 60 mg film-coated tablets; 2014; updated September 2014. Available at: http://www.medicines.org.uk/emc/medicine/29129. [Accessed 1 September 2015].
33. Nelson DR, Cooper JN, Lalezari JP, et al. Al l-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61:1127-1135.
34. European Medicines Agency. CHMP assessm ent report: Daklinza (international non-proprietary name: daclatasvir). Procedure no. EMEA/H/C/003768/0000; 2014. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-Assessment-report/human/003768/WC500172849.pd f. [Accessed 13 October 2015].
35. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
36. Poordad F, McCone J Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Me d 2011; 364:1195-1206.
37. Gilead Sciences International Ltd. Summary of product characteristics. Sovaldi® 400 mg film-coated tablets; 2014; updated June 2014. Available at: http://www.medicines.org.uk/emc/medicine/28539/SPC/Sovaldi+400 +mg+film+coated+tablets/. [Accessed 1 September 2015].
38. Lawitz E,Mangia A,Wyles D,Rodriguez-Torres M,Hassanein T,Gordon SC,et al. Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 2013 368 1878-1887.
39. Janssen-Cilag Ltd. Summary of product characteristics. OLYSIO® 150 mg hard capsules; 2014. Available at: https://www.medicines.org.uk/emc/medicine/28888. [Accessed 1 September 2015].
40. Hadziyannis SJ, Sette H Jr., Morga n TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-Alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
41. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus gen otype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. The Lancet 2014; 384:1756-1765.
42. Moreno C, Hezode C, Marcellin P, Bourgeois S, Francque S, Samuel D, et al. Efficacy and safety of simeprevir with PegIFN/ribavirin in naive or experienced patients infected with chronic HCV genotype 4. J Hepatol 2015; 62:1047-1055.
43. Sh iffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126:1015-1023.
44. Hezode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 2014; 64:948-956.
45. Merck Sharp & Dohme Ltd. Summary of product characteristics. Victrelis® 200 mg hard capsules; 2013; updated June 2014. Ava ilable at: http://www.medicines.org.uk/emc/medicine/24768/SPC/Victrelis+200 +mg+hard+capsules/. [Accessed 1 September 2015].
46. Janssen-Cilag Ltd. Summary of product characteristics. Incivo® 375 mg film coated tab lets; 2013; updated June 2014. Available at: http://www.medicines.org.uk/emc/medicine/25038/SPC/INCIVO+ 375 +mg+film+coated+tablets/. [Accessed 1 September 2015].
47. Roche Products Ltd. Summary of produc t characteristics. Pegasys® 90 mcg, 135 mcg and 180 mcg solution for injection in pre-filled syringe/pre-filled pen; 2013; updated June 2014. Available at: http://www. medicines.org.uk/emc/medicine/10081/SPC/Pegasys+90mcg%2c+135mcg+a nd+180mcg++ solution+for+injection+in+Prefilled+Syringe+Pre-filled+Pen/. [Accessed 1 September 2015].
48. Merck Sharp & Dohme Ltd. Summary of product characteristics. ViraferonPeg® Pen 50, 80, 100, 120 or 150 micrograms powder and solvent for solution for injection in pre-filled pen CLEAR CLICK; 2013; updated June 2014. Available at: http://www.medicines.org.uk/emc/medicine/28182/SPC/ViraferonPeg+Pen+50%2c+80 %2c+100%2c+120+or+150 +micrograms+powder+and+solvent+for+solution+for+injection+in+pre-filled+pen+CLEAR +CLICK/. [Accessed 1 September 2015].
49. Roche Products Ltd. Summary of product characteristics. Copegus® 200 mg and 400 mg film-coated tablets; 2012; updated June 2014. Available at: http://www.medicines.org.uk/emc/medicine/11755/SPC/Copegus+200mg+and+400mg+Film-coated+Tablets/. [Accessed 1 September 2015].
50. Merck Sharp & Dohme Ltd. Summary of product characteristics. Rebetol® 200 mg hard capsules; 2013; updated June 2014. Available at: http://www.medicines.org.uk/emc/medicine/3237/SPC/Rebetol+200mg+hard++ c apsules/. [Accessed 1 September 2015].
51. Na tional Institute for Health and Care Excellence. Technology appraisal 75. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C; 2004. Available at: http://www.nice. org.uk/guidance /TA75. [Accessed 1 September 2015].
52. National Institute for Health and Care Excellence. Technology appraisal 106. Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C; 2006. Available at: http://www.nice.org.uk/guidance/TA106. [Accessed 1 September 2015].
53. National Institute for Health and Care Excellence. Technology appraisal 200. Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C; 2010. Available at: http://www.nice.org.uk/guidance/TA200. [Accessed 1 September 2015].
54. National Institute of Health and Care Excellence. Technology appraisal 252. Telap revir for the treatment of genotype 1 chronic hepatitis C; 2012; updated June 2014. Available at: http://www.nice.org.uk/ta252. [Accessed 1 September 2015].
55. National Institute of Health and Care Exc ellence. Technology appraisal 253. Boceprevir for the treatment of genotype 1 chronic hepatitis C; 2012; updated June 2014. Available at: http://www.nice.org.uk/ta253. [Accessed 1 September 2015].
56. N ational Institute for Health and Care Excellence. Hepatitis C (chronic)-sofosbuvir [ID654]; 2014. Available at: http://www.nice.org.uk/gui dance/indevelopment/GID-TAG445. [Accessed 1 September 2015].
57. National I nstitute for Health and Care Excellence. Hepatitis C (chronic)-simeprevir [ID668]; 2014. Available at: http://www.nice.org.uk/gui dance/indevelopment/GID-TAG455. [Accessed 1 September 2015].
58. National Insti tute for Health and Care Excellence. Guide to the methods of technology appraisal 2013; 2013. Available at: http://www.nice.org. uk/article/pmg9. [Accessed 1 September 2015].
59. ClinicalTrials.gov UNIoH NCT02032875: Phase III daclatasvir, sofosbuvir, and ribavirin in cirrhotic subjects and subjects post-liver transplant (ALLY 1) 2015. Available at https://clinicaltrials.gov/ct2/show/NCT02032875? term=ally+1&rank=1. [Accessed 1 September 2015].
60. ClinicalTrials.gov UNIoH. NCT02032888: Phase III HIV/HCV co-infection daclatasvir (DCV)+ sofosbuvir (SOF) (ALLY 2); 2015. Available at: https://clinicaltrials.gov/ct2/s how/NCT02032888?term = ALLY+2&rank=1. [Accessed 1 September 2015].
61. US Department of Veterans Affairs. Interferon and ribavirin treatment side effects; 2014. Available at: http://www.hepatitis.va.gov/provi der/reviews/treatment-side-effects.asp. [Accessed 1 September 2015].